TenderlineUK
Procurement Intelligence
Search
Find a TenderAwardedContract details notice
Published 26 Aug 2025, 17:01 BST

Official UK procurement notice

NHS National Framework Agreement for Omalizumab

Official notice

Authority: NHS England (Central government)

Framework agreementGoodsOpen procedureAbove thresholdSME suitable
Sectors: Medical Devices & Pharma (33) Delivery: North East (UKC)North West (UKD)East Midlands (UKF)
+4 moreWest Midlands (UKG)East of England (UKH)South East (UKJ)South West (UKK)
Framework ceiling (notional)£85,785,000framework ceiling, not attributable revenue · 1 value update
Submissions closed 30 Oct 2025awarded 26 Nov 2025
Award (standstill) to Celltrion Healthcare United Kingdom Limited +2 more
Framework period 1 yr 7 moends 31 Aug 2027 · up to 31 Aug 2029 with extensions · starts 1 Feb 2026

Re-procurement plannedNHS National Framework for Ivacaftor · tender expected

What is being bought

Published requirement description

Project title: NHS National Framework for Omalizumab commencing 1st February 2026

Offer reference number: CM/TNS/25/5734

Period of framework: 1 February 2026 to 31 August 2027 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.

Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England

CPV: Pharmaceutical products

How this framework works

From the published notice
Type
Closed framework
Call-offs
every call-off is a further competition among the appointed suppliers
Bids received
3 bids received · 3 suppliers appointed
Framework period
1 yr 7 mo · up to 3 yrs 7 mo from 1 Feb 2026
Who may buy through it

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points.

Published description of the framework

Please refer to the ITO Documents for the Operation Description

The lotProcurement structure

single lot · value published
Lot #1AwardedRenewal 1 yr 7 moSMEPublished value£85,785,000
Contract period: 1 Feb 2026 – 31 Aug 2027 (1 yr 7 mo) · up to 31 Aug 2029 with extensionsValue: £85,785,000 exc. VAT · £102,942,000 inc. VAT
Delivery: North East, North West, East Midlands, West Midlands, East of England, South East, South WestEligibility: SME eligible
Extensions: Option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.
33600000 Pharmaceutical products

What it takes to win
i

How this buyer will score bids.

The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).

Evaluation split and conditions of participation as published; the tender pack may add more
How bids were scored
Price: 100%
Published sub-criteria (1)
  • Price is not the only award criterion: 100%
Published award criteria (1)
  • Price is not the only award criterion
What this means for your bid
  • Price carries 100 of 100 points: a 10% discount moves about 10 points. This one is won on the number: sharpen the price before polishing the prose.
  • “NHS National Framework Agreement for Omalizumab” is a framework: the contest is a place on its panel, not a single contract: each call-off is a further competition, so the pricing contest starts after appointment.

Price arithmetic assumes straight proportional scoring; the tender pack may use another formula.

Procedure terms & legal framework

From the official record
Procedure method
Open procedure
Legal basis
UKPGA · 2023/54 Procurement Act 2023
Procurement category
Goods
Notice status
Awarded
Procurement threshold
Above threshold (FTS publication)
Regulatory regime
Standard
Commercial structure
Framework agreement
Who may use this agreement
Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points.
Competition type
Competitive procedure
GPA / WTO covered
Yes (GPA)
Recurring procurement
Unspecified in notice
First published
26 Aug 2025, 17:01 BST
Last source update
30 Dec 2025, 16:29 GMT
Award evaluation window
Submission end – 26 Nov 2025
Authority reference
C382504
FTS notice number
2025/S 000-061970
Latest notice
Contract details notice (UK7)
Classification (CPV)
Pharmaceutical products
Delivery area
North East (UKC)North West (UKD)East Midlands (UKF)West Midlands (UKG)East of England (UKH)South East (UKJ)South West (UKK)
Official registry OCID
ocds-h6vhtk-058e04 Find a Tender

How it was run

Official notice
Run through: Atamis legacy domain (health-family.force.com) · Who buys & how to bid on Atamis
Supplier login requiredElectronic submission allowedLanguage: EN
Access & registration note: Legacy Salesforce domain still used in notices — use the current Atamis portal · this portal address is a legacy domain; the operator has migrated
Appointment period ends
30 Oct 2025, 13:00 GMT
Clarification deadline
23 Oct 2025, 13:00 BST
Submission channel
Official e-sourcing portal
Electronic submission
Allowed
Accepted languages
en
Detailed submission instructions & authority contactsFrom official release

The procurement documents are available for unrestricted and full direct access, free of charge at health-family.force.com/s/Welcome ↗

Additional info obtained from the abovementioned address

Tenders must be submitted to the abovementioned address

Timeline

26 Aug 2025 → 1 Feb 2026 · 11 dates
  1. Planning notice published
    26 Aug 2025, 17:01 BST
  2. Market engagement399 days ago
    18 Sept 2025, 23:59 BST

    NHS England is seeking to engage with suppliers that are planning to launch Omalizumab injection. Interested suppliers will be invited to a virtual PME meeting to be held on Thursday 18th September 2025

    The purpose of these sessions is to update suppliers regarding timelines and to discuss product details, product launches during the proposed framework period, tender structure, and KPI's.

    Please contact [email protected] or [email protected] to register your interest in tendering for this framework.

  3. Next notice expected386 days ago
    1 Oct 2025, 23:59 BST
  4. Tender notice published385 days ago
    3 Oct 2025, 08:53 BST
  5. Clarification questions by365 days ago
    23 Oct 2025, 13:00 BST
  6. Admission / appointment period ends357 days ago · period end, not a bid countdown
    30 Oct 2025, 13:00 GMT
  7. Award decision expected by330 days ago
    26 Nov 2025, 23:59 GMT
  8. Assessment summaries sent329 days ago
    28 Nov 2025
  9. Standstill ends316 days ago
    10 Dec 2025, 23:59 GMT
  10. Latest notice published296 days ago
    30 Dec 2025, 16:29 GMT
  11. Contract starts264 days ago
    1 Feb 2026

Notice history

10 events · 4 releases on Find a Tender · since 26 Aug 2025
  1. Preliminary market engagement notice published
    26 Aug 2025, 17:01 BST
    UK2
  2. Tender notice published
    3 Oct 2025, 08:53 BST
    UK4
  3. Published value updated to £85,785,000
    3 Oct 2025, 08:53 BST
    was £125,417,000
  4. Status changed to active
    3 Oct 2025, 08:53 BST
  5. Procurement method changed
    3 Oct 2025, 08:53 BST
  6. Deadline published: 30 Oct 2025, 13:00 GMT
    3 Oct 2025, 08:53 BST
  7. Contract award notice published
    28 Nov 2025, 12:23 GMT
    UK6
  8. Status changed to complete
    28 Nov 2025, 12:23 GMT
  9. Contract signature expected
    23 Dec 2025, 23:59 GMT
    scheduled
  10. Contract details notice published
    30 Dec 2025, 16:29 GMT
    UK7
Routine re-releases (4)
  • 2025-08: 1 release · 26 Aug 2025

Commercial outcome & contract awards

Published awards, contracts and bid statistics, not a forecast
Suppliers appointed 32 awards · see the list ↓
Bids received 3
Named bidders 3published on the award notice
Contracts signed 1latest 12 Dec 2025
Awarded toValueDateStatus
Celltrion Healthcare United Kingdom Limited, Mercury Pharmaceuticals Limited, NOVARTIS PHARMACEUTICALS UK LIMITEDLot 1 - CM/TNS/25/57341 Feb 2026 – 31 Aug 2027 · up to 31 Aug 2029Extensions: Option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.£87,433,00026 Nov 2025standstill to 10 Dec 2025Standstill

Contracts

  • Lot 1 - CM/TNS/25/5734

    Signed
    12 Dec 2025
    Value
    £87,433,000
    Period
    1 Feb 2026 – 31 Aug 2027 · up to 31 Aug 2029 with extensions
    Status
    active
    Extensions
    Option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.

Bid statistics published by the authority

BidsSMEVCSEValid bid range
3final-stage tenders00—

Who bid

Bidders as named on the Procurement Act 2023 award notice. “Won” means the bidder holds an award on this notice.

Contracting authority & participating public bodies

NHS England

Contracting authorityPublic authority - central government GB-PPON: PDPT-3135-BWWY Wellington House, 133-135 Waterloo Rd, London, London, SE1 8UGContact name, email

Framework contractors & participating bidders

3 commercial parties on the notice

Official documents & specifications (17)

Official links; attachments are not copied

Tender pack and attachments

Show 5 more documents

Notices published for this procedure